BAY 1895344

Drug Profile

BAY 1895344

Alternative Names: BAY1895344

Latest Information Update: 14 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer
  • Class Antineoplastics; Naphthyridines; Small molecules
  • Mechanism of Action ATR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lymphoma; Solid tumours
  • Preclinical Cancer

Most Recent Events

  • 06 Jul 2017 Phase-I clinical trials in Lymphoma (Late-stage disease) in Singapore (unspecified route) (NCT03188965)
  • 06 Jul 2017 Phase-I clinical trials in Solid tumours (Late-stage disease) in Singapore (unspecified route) (NCT03188965)
  • 21 Jun 2017 Bayer plans a phase I trial for Solid tumours and Lymphoma(Late-stage disease) in USA, Singapore and United Kingdom (NCT03188965)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top